<p>With 29.75 times subscription on the last day of bidding, Valiant Laboratories Ltd.’s initial public offering (IPO), which was up for subscription between September 27 and October 3, garnered a respectable response. According to the most recent NSE statistics, bids were received for 22,68,13,020 of the 76,23,030 shares that were being offered.<img decoding=”async” class=”alignnone wp-image-218117″ src=”https://www.theindiaprint.com/wp-content/uploads/2023/10/theindiaprint.com-thai-pm-promises-preventive-measures-following-bangkok-mall-shooting-download-2023.jpg” alt=”theindiaprint.com thai pm promises preventive measures following bangkok mall shooting download 2023″ width=”1266″ height=”709″ srcset=”https://www.theindiaprint.com/wp-content/uploads/2023/10/theindiaprint.com-thai-pm-promises-preventive-measures-following-bangkok-mall-shooting-download-2023.jpg 300w, https://www.theindiaprint.com/wp-content/uploads/2023/10/theindiaprint.com-thai-pm-promises-preventive-measures-following-bangkok-mall-shooting-download-2023-150×84.jpg 150w” sizes=”(max-width: 1266px) 100vw, 1266px” title=”Valiant Laboratories IPO: View Final Subscription Status and GMP Today 18″></p>
<p>The quota for qualified institutional purchasers obtained a 20.83 times subscription while the share for non-institutional investors earned a 73.63 times subscription. The part for retail individual investors was resubscribed 16.05 times.</p>
<p>On October 5, the IPO will be allocated, and on October 9, it will be listed on the BSE and NSE.</p>
<p>GMP Today: Valiant Laboratories IPO</p>
<p>Market watchers claim that unlisted Valiant Laboratories Ltd. shares are presently selling on the grey market for Rs. 25 more than their issue price. The grey market premium, or GMP, of Rs. 25 is about 17.86% more than the share’s maximum issuance price of Rs. 140. This indicates that the grey market anticipates a 17.86% listing gain from the public offering.</p>
<p>Investors’ willingness to pay more than the issue price is indicated by the term “grey market premium.”</p>
<p>Details of the Valiant Laboratories IPO</p>
<p>Up to 1.08 crore equity shares were issued in the IPO, which was a completely new issue. The offer’s price per share ranged from Rs 133 to 140.</p>
<p>Through its subsidiary, Valiant Advanced Sciences Private Ltd., the proceeds of the offering will be used to establish a production facility for specialty chemicals in Gujarat and to fulfill the working capital needs of the subsidiary firm.</p>
<p>With a concentration on producing paracetamol, which is used to treat headaches, muscular pains, arthritis, backaches, toothaches, colds, and fever, Valiant Laboratories is a firm that produces active pharmaceutical ingredients or bulk drugs.</p>
<p>The offer was managed by Unistone Capital.</p>
<p>The company’s equity shares will be listed on the BSE and the NSE.</p>
<p> </p>
